FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

George Drusano

Research Profile

Procedures

Chemicals & Drugs

Concepts & Ideas

Physiology

Bacterial Drug Resistance

Living Beings

Disorders

Co-author Network

Publications

TOP 3
George L Drusano; Thomas P Lodise
Saving lives with optimal antimicrobial chemotherapy.
Cornelia Landersdorfer; Ulrich Stephan; Jürgen Bulitta; George L Drusano; Ulrike Holzgrabe; Martina Kinzig; Carl M J Kirkpatrick; Fritz Sörgel
Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.
Marilyn N Martinez; Mark G Papich; George L Drusano
Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of George Drusano (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: George L Drusano; Thomas P Lodise
Saving lives with optimal antimicrobial chemotherapy.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2013;56(2):245-7.
2012: Cornelia Landersdorfer; Ulrich Stephan; Jürgen Bulitta; George L Drusano; Ulrike Holzgrabe; Martina Kinzig; Carl M J Kirkpatrick; Fritz Sörgel
Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.
Antimicrobial agents and chemotherapy 2012;56(11):5715-23.
2012: Marilyn N Martinez; Mark G Papich; George L Drusano
Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target.
Antimicrobial agents and chemotherapy 2012;56(6):2795-805.
2012: George L Drusano
Early endpoints for acute bacterial skin and skin structure infections.
Antimicrobial agents and chemotherapy 2012;56(5):2221-2.
2012: Paul G Ambrose; Sujata M Bhavnani; Michael N Dudley; Evelyn Ellis-Grosse; Christopher M Rubino; George L Drusano
New EMA guideline for antimicrobial development.
The Lancet infectious diseases 2012;12(4):265-6.
2012: Paul G Ambrose; George L Drusano; William A Craig
In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2012;54 Suppl 3():S220-8.
2012: Ashley N Brown; A Corbin; Jonathan R Adams; Richard J O Barnard; Daria J Hazuda; Robert Kulawy; Arnold Louie; James J McSharry; W Newhard; George L Drusano
Pharmacodynamic analysis of a serine protease inhibitor, MK-4519, against hepatitis C virus using a novel in vitro pharmacodynamic system.
Antimicrobial agents and chemotherapy 2012;56(3):1170-81.
2012: Paul G Ambrose; Sujata M Bhavnani; Evelyn J Ellis-Grosse; Jeffrey P Hammel; Christopher M Rubino; George L Drusano
Frequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: overcoming lies, damn lies, and statistics.
Antimicrobial agents and chemotherapy 2012;56(3):1466-70.
2012: Arnold Louie; Brian D VanScoy; David L Brown; Henry S Heine; Robert W Kulawy; George L Drusano
Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model.
Antimicrobial agents and chemotherapy 2012;56(3):1229-39.
2012: Anthony M Nicasio; Jürgen Bulitta; Rebecca E D'Hondt; Robert W Kulawy; Thomas P Lodise; Arnold Louie; George L Drusano
Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model.
Antimicrobial agents and chemotherapy 2012;56(2):682-6.
2012: Katie E Cardone; Rachid Daoui; George L Drusano; Darren W Grabe; Robert W Kulawy; Shari Meola; Joseph Roglieri; Thomas P Lodise
Ertapenem pharmacokinetics and pharmacodynamics during continuous ambulatory peritoneal dialysis.
Antimicrobial agents and chemotherapy 2012;56(2):725-30.
2011: Thomas P Lodise; Jill M Butterfield; George L Drusano; Mark H Gotfried; Joshua Scoville; Keith A Rodvold
Penetration of vancomycin into epithelial lining fluid in healthy volunteers.
Antimicrobial agents and chemotherapy 2011;55(12):5507-11.
2011: Jill M Butterfield; George L Drusano; Manjunath P Pai; Nimish Patel; Thomas G Rosano; Thomas P Lodise
Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding.
Antimicrobial agents and chemotherapy 2011;55(9):4277-82.
2011: George L Drusano; Weiguo Liu; T P Lodise; D Melnick; A Mena; A Oliver; B VanScoy; Arnold Louie
Meropenem penetration into epithelial lining fluid in mice and humans and delineation of exposure targets.
Antimicrobial agents and chemotherapy 2011;55(7):3406-12.
2011: Arnold Louie; Daniel S Stein; Brian D Vanscoy; Julia Z Zack; Haley Conde; Christine Fregeau; Weiguo Liu; George L Drusano
Dose range evaluation of Mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis.
Antimicrobial agents and chemotherapy 2011;55(7):3295-304.
2011: Arnold Louie; Robert Kulawy; Weiguo Liu; George L Drusano
In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model.
Antimicrobial agents and chemotherapy 2011;55(7):3453-60.
2011: Arnold Louie; Brian Vanscoy; Weiguo Liu; Robert Kulawy; David Brown; Henry S Heine; George L Drusano
Comparative efficacies of candidate antibiotics against Yersinia pestis in an in vitro pharmacodynamic model.
Antimicrobial agents and chemotherapy 2011;55(6):2623-8.
2011: George L Drusano; B Vanscoy; Weiguo Liu; S Fikes; D Brown; Arnold Louie
Saturability of granulocyte kill of Pseudomonas aeruginosa in a murine model of pneumonia.
Antimicrobial agents and chemotherapy 2011;55(6):2693-5.
2011: George L Drusano; Arnold Louie
Optimization of aminoglycoside therapy.
Antimicrobial agents and chemotherapy 2011;55(6):2528-31.
2011: Katie E Cardone; Thomas P Lodise; Nimish Patel; Christopher D Hoy; Shari Meola; Harold J Manley; George L Drusano; Darren W Grabe
Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis.
Clinical journal of the American Society of Nephrology : CJASN 2011;6(5):1081-8.
2011: Nimish Patel; Manjunath P Pai; Keith A Rodvold; Ben Lomaestro; George L Drusano; Thomas P Lodise
Vancomycin: we can't get there from here.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2011;52(8):969-74.
2011: George L Drusano
What are the properties that make an antibiotic acceptable for therapy of community-acquired pneumonia?
The Journal of antimicrobial chemotherapy 2011;66 Suppl 3():iii61-7.
2011: Johan W Mouton; Paul G Ambrose; Rafael Canton; George L Drusano; Stephan Harbarth; Alasdair MacGowan; Ursula Theuretzbacher; John Turnidge
Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2011;14(2):107-17.
2011: T P Lodise; F Sorgel; D Melnick; B Mason; M Kinzig; George L Drusano
Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia.
Antimicrobial agents and chemotherapy 2011;55(4):1606-10.
2011: Nimish Patel; Katie Cardone; Darren W Grabe; Shari Meola; Christopher Hoy; Harold J Manley; George L Drusano; Thomas P Lodise
Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis.
Antimicrobial agents and chemotherapy 2011;55(4):1677-83.
2011: Ashley N Brown; James J McSharry; Qingmei Weng; Jonathan R Adams; Robert Kulawy; George L Drusano
Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system.
Antimicrobial agents and chemotherapy 2011;55(4):1740-6.
2011: Ashley N Brown; Jürgen B Bulitta; James J McSharry; Qingmei Weng; Jonathan R Adams; Robert Kulawy; George L Drusano
Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model.
Antimicrobial agents and chemotherapy 2011;55(4):1747-53.
2011: Arnold Louie; Henry S Heine; B VanScoy; A Eichas; K Files; S Fikes; D L Brown; Weiguo Liu; M Kinzig-Schippers; F Sörgel; George L Drusano
Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.
Antimicrobial agents and chemotherapy 2011;55(2):822-30.
2011: James J McSharry; George L Drusano
Antiviral pharmacodynamics in hollow fibre bioreactors.
Antiviral chemistry & chemotherapy 2011;21(5):183-92.
2011: Hung-Yun Lin; Cornelia Landersdorfer; David London; Ran Meng; Chang-Uk Lim; Cassie Lin; Sharon Lin; Heng-Yuan Tang; David Brown; Brian Van Scoy; Robert Kulawy; Lurdes Queimado; George L Drusano; Arnold Louie; Faith B Davis; Shaker A Mousa; Paul J Davis
Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system.
PLoS computational biology 2011;7(2):e1001073.
2010: George L Drusano
Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity.
The Journal of antimicrobial chemotherapy 2010;65 Suppl 4():iv33-9.
2010: Lois S Lee; Martina Kinzig; Anne N Nafziger; Lei Ma; Fritz Sörgel; Ronald N Jones; George L Drusano; Joseph S Bertino
Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
Diagnostic microbiology and infectious disease 2010;68(3):251-8.
2010: Nimish Patel; Marc H Scheetz; George L Drusano; Thomas P Lodise
Determination of antibiotic dosage adjustments in patients with renal impairment: elements for success.
The Journal of antimicrobial chemotherapy 2010;65(11):2285-90.
2010: George L Drusano; Christine Fregeau; Weiguo Liu; D L Brown; Arnold Louie
Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection model.
Antimicrobial agents and chemotherapy 2010;54(10):4368-72.
2010: Paul G Ambrose; Sujata M Bhavnani; Evelyn J Ellis-Grosse; George L Drusano
Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap!
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010;51 Suppl 1():S103-10.
2010: Ashley N Brown; James J McSharry; Qingmei Weng; Elizabeth M Driebe; David M Engelthaler; Kelly Sheff; Paul Keim; Jack Nguyen; George L Drusano
In vitro system for modeling influenza A virus resistance under drug pressure.
Antimicrobial agents and chemotherapy 2010;54(8):3442-50.
2010: Sujata M Bhavnani; Christopher M Rubino; Paul G Ambrose; George L Drusano
Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010;50(12):1568-74.
2010: Arnold Louie; Caroline Grasso; Nadzeya Bahniuk; Brian Van Scoy; David L Brown; Robert W Kulawy; George L Drusano
The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression.
Antimicrobial agents and chemotherapy 2010;54(6):2646-54.
2010: Arnold Louie; Adam Bied; Christine Fregeau; Brian Van Scoy; David Brown; Weiguo Liu; Karen Bush; Anne-Marie Queenan; Brian Morrow; Mohammed Khashab; James B Kahn; Susan Nicholson; Robert W Kulawy; George L Drusano
Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance.
Antimicrobial agents and chemotherapy 2010;54(6):2638-45.
2010: Sujata M Bhavnani; Christopher M Rubino; Paul G Ambrose; T J Babinchak; Joan Korth-Bradley; George L Drusano
Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections.
Antimicrobial agents and chemotherapy 2010;54(3):1207-12.
2009: George L Drusano; O O Okusanya; A O Okusanya; B van Scoy; D L Brown; C Fregeau; R Kulawy; M Kinzig; F Sörgel; Henry S Heine; Arnold Louie
Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
Antimicrobial agents and chemotherapy 2009;53(11):4718-25.
2009: Jürgen B Bulitta; Stephen B Duffull; Cornelia Landersdorfer; Martina Kinzig; Ulrike Holzgrabe; Ulrich Stephan; George L Drusano; Fritz Sörgel
Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers.
Diagnostic microbiology and infectious disease 2009;65(2):130-41.
2009: Cornelia Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig; Jürgen Bulitta; Ulrike Holzgrabe; George L Drusano; Fritz Sörgel
Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid.
Antimicrobial agents and chemotherapy 2009;53(9):3902-7.
2009: Thomas P Lodise; Nimish Patel; Ben M Lomaestro; Keith A Rodvold; George L Drusano
Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;49(4):507-14.
2009: Keith A Rodvold; David P Nicolau; Thomas P Lodise; Mohammed Khashab; Gary J Noel; James B Kahn; Mark H Gotfried; Sara A Murray; Susan Nicholson; Somvadee Laohavaleeson; Pamela R Tessier; George L Drusano
Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.
Antimicrobial agents and chemotherapy 2009;53(8):3294-301.
2009: Arnold Louie; Christine Fregeau; Weiguo Liu; Robert W Kulawy; George L Drusano
Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets.
Antimicrobial agents and chemotherapy 2009;53(8):3325-30.
2009: James J McSharry; Qingmei Weng; Ashley Brown; Robert Kulawy; George L Drusano
Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system.
Antimicrobial agents and chemotherapy 2009;53(6):2375-81.
2009: George L Drusano; Weiguo Liu; Christine Fregeau; Robert Kulawy; Arnold Louie
Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant.
Antimicrobial agents and chemotherapy 2009;53(6):2266-73.
2009: Cornelia Landersdorfer; Martina Kinzig; Friedrich F Hennig; Jürgen Bulitta; Ulrike Holzgrabe; George L Drusano; Fritz Sörgel; Johannes Gusinde
Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
Antimicrobial agents and chemotherapy 2009;53(5):2074-81.
2009: Hung-Yun Lin; Mingzeng Sun; Heng-Yuan Tang; Cassie Lin; Mary K Luidens; Shaker A Mousa; Sandra Incerpi; George L Drusano; Faith B Davis; Paul J Davis
L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase.
American journal of physiology. Cell physiology 2009;296(5):C980-91.
2009: James J McSharry; Mark R Deziel; Kris Zager; Qingmei Weng; George L Drusano
Pharmacodynamics of cidofovir for vaccinia virus infection in an in vitro hollow-fiber infection model system.
Antimicrobial agents and chemotherapy 2009;53(1):129-35.
2008: George L Drusano; Olanrewaju O Okusanya; Adedoyin Okusanya; Brian Van Scoy; D L Brown; Robert Kulawy; Fritz Sörgel; Henry S Heine; Arnold Louie
Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis?
Antimicrobial agents and chemotherapy 2008;52(11):3973-9.
2008: Catherine A A Beauchemin; James J McSharry; George L Drusano; Jack T Nguyen; Gregory T Went; Ruy M Ribeiro; Alan S Perelson
Modeling amantadine treatment of influenza A virus in vitro.
Journal of theoretical biology 2008;254(2):439-51.
2008: Sujata M Bhavnani; Alan Forrest; Jeffrey P Hammel; George L Drusano; Christopher M Rubino; Paul G Ambrose
Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia.
Diagnostic microbiology and infectious disease 2008;62(1):99-101.
2008: Arnold Louie; Henry S Heine; K Kim; D L Brown; B VanScoy; Weiguo Liu; M Kinzig-Schippers; F Sörgel; George L Drusano
Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis.
Antimicrobial agents and chemotherapy 2008;52(7):2486-96.
2008: Thomas P Lodise; Mark Gotfried; Steven Barriere; George L Drusano
Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation.
Antimicrobial agents and chemotherapy 2008;52(7):2300-4.
2008: Thomas P Lodise; Martina Kinzig; George L Drusano; Ulrich Loos; Friedrich Vogel; Jürgen Bulitta; Markus Hinder; Fritz Sörgel
Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
Antimicrobial agents and chemotherapy 2008;52(6):1945-51.
2008: Paul G Ambrose; Jack B Anon; Sujata M Bhavnani; Olanrewaju O Okusanya; Ronald Jones; Margaret R Paglia; James Kahn; George L Drusano
Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis.
Diagnostic microbiology and infectious disease 2008;61(1):13-20.
2008: Thomas P Lodise; Ben M Lomaestro; Jeffrey Graves; George L Drusano
Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity.
Antimicrobial agents and chemotherapy 2008;52(4):1330-6.
2008: Tawanda Gumbo; John Hiemenz; Lei Ma; James J Keirns; Donald N Buell; George L Drusano
Population pharmacokinetics of micafungin in adult patients.
Diagnostic microbiology and infectious disease 2008;60(3):329-31.
2008: William W Hope; Diana Mickiene; Vidmantas Petraitis; Ruta Petraitiene; Amy M Kelaher; Joanna E Hughes; Margaret P Cotton; John Bacher; James J Keirns; Donald N Buell; Gloria Heresi; Daniel K Benjamin; Andreas H Groll; George L Drusano; THOMAS WALSH
The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates.
The Journal of infectious diseases 2008;197(1):163-71.
2007: Paul G Ambrose; Alan Forrest; William A Craig; Christopher M Rubino; Sujata M Bhavnani; George L Drusano; Henry S Heine
Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model.
Antimicrobial agents and chemotherapy 2007;51(12):4351-5.
2007: Arnold Louie; David L Brown; Weiguo Liu; Robert W Kulawy; Mark R Deziel; George L Drusano
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
Antimicrobial agents and chemotherapy 2007;51(11):3988-4000.
2007: Christopher M Rubino; Lei Ma; Sujata M Bhavnani; Joan Korth-Bradley; John Speth; Evelyn J Ellis-Grosse; Keith A Rodvold; Paul G Ambrose; George L Drusano
Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
Antimicrobial agents and chemotherapy 2007;51(11):4085-9.
2007: Thomas P Lodise; R Nau; Martina Kinzig; George L Drusano; Ronald Jones; Fritz Sörgel
Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation.
The Journal of antimicrobial chemotherapy 2007;60(5):1038-44.
2007: Tawanda Gumbo; Arnold Louie; Mark R Deziel; Weiguo Liu; Linda M Parsons; Max Salfinger; George L Drusano
Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin.
Antimicrobial agents and chemotherapy 2007;51(11):3781-8.
2007: William W Hope; Peter A Warn; Andrew Sharp; Paul Reed; Brian Keevil; Arnold Louie; THOMAS WALSH; David W Denning; George L Drusano
Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing.
Antimicrobial agents and chemotherapy 2007;51(10):3760-2.
2007: William W Hope; Nita L Seibel; Cindy L Schwartz; Antonio Arrieta; Patricia Flynn; Aziza Shad; Edythe Albano; James J Keirns; Donald N Buell; Tawanda Gumbo; George L Drusano; THOMAS WALSH
Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing.
Antimicrobial agents and chemotherapy 2007;51(10):3714-9.
2007: George L Drusano; Paul G Ambrose; Sujata M Bhavnani; Joseph S Bertino; Ann N Nafziger; Arnold Louie
Back to the future: using aminoglycosides again and how to dose them optimally.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007;45(6):753-60.
2007: Monica M Parker; Daniel Gordon; Andrew Reilly; Harold W Horowitz; Mark Waters; Ryan Bennett; Renee Hallack; Joseph Smith; Daryl Lamson; Aida Aydemir; Natia Dvali; Bruce D Agins; George L Drusano; Jill Taylor
Prevalence of drug-resistant and nonsubtype B HIV strains in antiretroviral-naïve, HIV-infected individuals in New York State.
AIDS patient care and STDs 2007;21(9):644-52.
2007: Henry S Heine; Arnold Louie; Fritz Sorgel; Jennifer Bassett; Lynda Miller; Lawrence J Sullivan; Martina Kinzig; George L Drusano
Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.
The Journal of infectious diseases 2007;196(5):782-7.
2007: Samir G Sakka; Anna K Glauner; Jürgen Bulitta; Martina Kinzig; Wolfgang Pfister; George L Drusano; Fritz Sörgel
Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.
Antimicrobial agents and chemotherapy 2007;51(9):3304-10.
2007: Cornelia Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig; Jürgen Bulitta; Ulrike Holzgrabe; George L Drusano; Fritz Sörgel
Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin.
Antimicrobial agents and chemotherapy 2007;51(9):3290-7.
2007: Arnold Louie; Mark R Deziel; Weiguo Liu; George L Drusano
Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.
Antimicrobial agents and chemotherapy 2007;51(8):2661-7.
2007: Thomas P Lodise; Roland Nau; Martina Kinzig; Ronald Jones; George L Drusano; Fritz Sörgel
Comparison of the probability of target attainment between ceftriaxone and cefepime in the cerebrospinal fluid and serum against Streptococcus pneumoniae.
Diagnostic microbiology and infectious disease 2007;58(4):445-52.
2007: George L Drusano
Pharmacokinetics and pharmacodynamics of antimicrobials.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007;45 Suppl 1():S89-95.
2007: Jürgen Bulitta; S B Duffull; Martina Kinzig; Ulrike Holzgrabe; U Stephan; George L Drusano; Fritz Sörgel
Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.
Antimicrobial agents and chemotherapy 2007;51(7):2497-507.
2007: Tawanda Gumbo; Arnold Louie; Weiguo Liu; David Brown; Paul G Ambrose; Sujata M Bhavnani; George L Drusano
Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.
Antimicrobial agents and chemotherapy 2007;51(7):2329-36.
2007: Thomas P Lodise; Rienk Pypstra; James B Kahn; Bindu P Murthy; Hui C Kimko; Karen Bush; Gary J Noel; George L Drusano
Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.
Antimicrobial agents and chemotherapy 2007;51(7):2378-87.
2007: Vincent H Tam; Arnold Louie; T R Fritsche; Mark R Deziel; Weiguo Liu; D L Brown; L Deshpande; Robert Leary; Ronald Jones; George L Drusano
Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial.
The Journal of infectious diseases 2007;195(12):1818-27.
2007: Tawanda Gumbo; George L Drusano; Weiguo Liu; Robert W Kulawy; Christine Fregeau; Vasha Hsu; Arnold Louie
Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia.
Antimicrobial agents and chemotherapy 2007;51(3):968-74.
2007: William W Hope; Michael J Kruhlak; Caron A Lyman; Ruta Petraitiene; Vidmantas Petraitis; Andrea Francesconi; Miki Kasai; Diana Mickiene; Tin Sein; Joanne Peter; Amy M Kelaher; Johanna E Hughes; Margaret P Cotton; Catherine J Cotten; John Bacher; Sanjay Tripathi; Louis Bermudez; Timothy K Maugel; Patricia M Zerfas; John R Wingard; George L Drusano; THOMAS WALSH
Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy.
The Journal of infectious diseases 2007;195(3):455-66.
2007: Thomas P Lodise; Ben M Lomaestro; George L Drusano
Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007;44(3):357-63.
2007: Vincent H Tam; Arnold Louie; Mark R Deziel; Weiguo Liu; George L Drusano
The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance.
Antimicrobial agents and chemotherapy 2007;51(2):744-7.
2007: Tawanda Gumbo; Arnold Louie; Weiguo Liu; Paul G Ambrose; Sujata M Bhavnani; David Brown; George L Drusano
Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth.
The Journal of infectious diseases 2007;195(2):194-201.
2007: Paul G Ambrose; Sujata M Bhavnani; Christopher M Rubino; Arnold Louie; Tawanda Gumbo; Alan Forrest; George L Drusano
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007;44(1):79-86.
2007: William W Hope; George L Drusano; Caroline B Moore; Andrew Sharp; Arnold Louie; THOMAS WALSH; David W Denning; Peter A Warn
Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis.
Antimicrobial agents and chemotherapy 2007;51(1):285-95.
2006: Maylee Chen; Lei Ma; George L Drusano; Joseph S Bertino; Anne N Nafziger
Sex differences in CYP3A activity using intravenous and oral midazolam.
Clinical pharmacology and therapeutics 2006;80(5):531-8.
2006: L Mark Kao; Karen Bush; Roy Barnewall; James Estep; Frederic W Thalacker; Pamela H Olson; George L Drusano; Neil Minton; Shuchean Chien; Alex Hemeryck; Michael F Kelley
Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model.
Antimicrobial agents and chemotherapy 2006;50(11):3535-42.
2006: William W Hope; Peter A Warn; Andrew Sharp; Susan Howard; Miki Kasai; Arnold Louie; THOMAS WALSH; George L Drusano; David W Denning
Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect.
Antimicrobial agents and chemotherapy 2006;50(11):3680-8.
2006: Tawanda Gumbo; George L Drusano; Weiguo Liu; Lei Ma; Mark R Deziel; Michael F Drusano; Arnold Louie
Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis.
Antimicrobial agents and chemotherapy 2006;50(11):3695-700.
2006: Elias J Anaissie; Brahm H Segal; John Graybill; Carola Arndt; John R Perfect; Michael E Kleinberg; Peter Pappas; Danny Benjamin; Robert Rubin; Judith A Aberg; Elisabeth E Adderson; Felice C Adler-Shohet; Hamdi Akan; Murat Akova; Nikolaos G Almyroudis; Barbara D Alexander; David Andes; Antonio Arrieta; John W Baddley; Michelle A Barron; Howard Belzberg; Helen W Boucher; Thomas G Boyce; Arturo Casadevall; Pranatharthi H Chandrasekar; John D Cleary; Catherine Cordonnier; Oliver A Cornely; Manuel Cuenca-Estrella; Jennifer S Daly; Nicholas Daoura; David W Denning; Ben dePauw; Louis de Repentigny; Maria Cecilia Dignani; William E Dismukes; J Peter Donnelly; Gerald R Donowitz; Bertrand Dupont; George L Drusano; Michael Ellis; Ana Espinel-Ingroff; Jay A Fishman; Rhonda Fleming; Graeme Forrest; Mahmoud Ghannoum; Mitchell Goldman; Monica Grazziutti; John N Greene; Richard N Greenberg; Paul O Gubbins; Susan Hadley; Raoul Herbrecht; John W Hiemenz; William Hope; Durane R Hospenthal; Shahid Husain; James I Ito; Robert M Jacobson; Melissa Johnson; Michael R Keating; Daniel H Kett; Katherine Knapp; Dimitrios P Kontoyiannis; Vladimir C Krcmery; Robert Larsen; Michel Laverdiere; Per Ljungman; O Lortholary; Johan Maertens; Debbie Marriott; Gloria Mattiuzzi; Michael R McGinnis; Michele Morris; Marcio Nucci; Frank C Odds; George A Pankey; Thomas Patterson; Mike Pfaller; Raymond R Razonable; Annette C Reboli; Michael G Rinaldi; Glenn D Roberts; Juan Luis Rodriguez Tudela; Coleman Rotstein; Markus Ruhnke; Mindy Schuster; Shmuel Shoham; Irene G Sia; Nita Siebel; Fernanda Silviera; Nina Singh; Jack D Sobel; Joseph S Solomkin; Tania C Sorrell; William J Steinbach; Zelalem Temesgen; AnnaMaria Tortorano; Shahe Vartivarian; Paul VerWeij; Claudio Viscoli; Maria Anna Viviani; Randall C Walker; Joseph L Wheat; Joseph Wiley; Peter R Williamson; John R Wingard; Victor L Yu; Theoklis Zaoutis
Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;43(8):1031-9.
2006: Thomas P Lodise; Ben M Lomaestro; George L Drusano
Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists.
Pharmacotherapy 2006;26(9):1320-32.
2006: Kelly A Sprandel; George L Drusano; David W Hecht; John C Rotschafer; Larry H Danziger; Keith A Rodvold
Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole.
Diagnostic microbiology and infectious disease 2006;55(4):303-9.
2006: M Chen; Anne N Nafziger; George L Drusano; L Ma; Joseph S Bertino
Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults.
Antimicrobial agents and chemotherapy 2006;50(4):1222-7.
2006: Thomas P Lodise; Denise H Rhoney; Vincent H Tam; Peggy S McKinnon; George L Drusano
Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies.
Diagnostic microbiology and infectious disease 2006;54(3):223-30.
2006: George L Drusano; Arnold Louie; Mark R Deziel; Tawanda Gumbo
The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;42(4):525-32.
2006: Nelson L Jumbe; Arnold Louie; Michael H Miller; Weiguo Liu; Mark R Deziel; Vincent H Tam; Reetu Bachhawat; George L Drusano
Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae.
Antimicrobial agents and chemotherapy 2006;50(1):310-7.
2005: George L Drusano
Infection site concentrations: their therapeutic importance and the macrolide and macrolide-like class of antibiotics.
Pharmacotherapy 2005;25(12 Pt 2):150S-158S.
2005: Mark R Deziel; Henry S Heine; Arnold Louie; Mark Kao; William R Byrne; Jennifer Basset; Lynda Miller; Karen Bush; Michael Kelly; George L Drusano
Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis.
Antimicrobial agents and chemotherapy 2005;49(12):5099-106.
2005: Arnold Louie; Mark R Deziel; Weiguo Liu; Michael F Drusano; Tawanda Gumbo; George L Drusano
Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.
Antimicrobial agents and chemotherapy 2005;49(12):5058-68.
2005: Jeffrey L Blumer; Michael D Reed; Edward L Kaplan; George L Drusano
Explaining the poor bacteriologic eradication rate of single-dose ceftriaxone in group a streptococcal tonsillopharyngitis: a reverse engineering solution using pharmacodynamic modeling.
Pediatrics 2005;116(4):927-32.
2005: William W Hope; Peter A Warn; Andrew Sharp; Paul Reed; Brian Keevil; Arnold Louie; David W Denning; George L Drusano
Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis.
The Journal of infectious diseases 2005;192(4):673-80.
2005: Tawanda Gumbo; Arnold Louie; Mark R Deziel; George L Drusano
Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance.
Antimicrobial agents and chemotherapy 2005;49(8):3178-81.
2005: Vincent H Tam; Arnold Louie; Mark R Deziel; Weiguo Liu; Robert Leary; George L Drusano
Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa.
The Journal of infectious diseases 2005;192(3):420-8.
2005: Thomas P Lodise; Sandra Preston; Vijay Bhargava; André Bryskier; Roomi Nusrat; Sonny Chapel; Manickam Rangaraju; George L Drusano
Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens.
Diagnostic microbiology and infectious disease 2005;52(1):45-52.
2005: Wolfgang A Krueger; Jürgen Bulitta; Martina Kinzig; Cornelia Landersdorfer; Ulrike Holzgrabe; Kurt G Naber; George L Drusano; Fritz Sörgel
Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.
Antimicrobial agents and chemotherapy 2005;49(5):1881-9.
2005: Johan W Mouton; Michael N Dudley; Otto Cars; Hartmut Derendorf; George L Drusano
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.
The Journal of antimicrobial chemotherapy 2005;55(5):601-7.
2005: Ben M Lomaestro; George L Drusano
Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation.
Antimicrobial agents and chemotherapy 2005;49(1):461-3.
2004: Thomas P Lodise; Ben M Lomaestro; Keith A Rodvold; Larry H Danziger; George L Drusano
Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation.
Antimicrobial agents and chemotherapy 2004;48(12):4718-24.
2004: Tawanda Gumbo; Arnold Louie; Mark R Deziel; Linda M Parsons; Max Salfinger; George L Drusano
Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
The Journal of infectious diseases 2004;190(9):1642-51.
2004: George L Drusano
How does a patient maximally benefit from anti-infective chemotherapy?
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(8):1245-6.
2004: A P Ball; John G Bartlett; W A Craig; George L Drusano; D Felmingham; Javier Garau; keith klugman; Donald E Low; Lionel A Mandell; E Rubinstein; G S Tillotson
Future trends in antimicrobial chemotherapy: expert opinion on the 43rd ICAAC.
Journal of chemotherapy (Florence, Italy) 2004;16(5):419-36.
2004: Holly M Mattoes; Joseph L Kuti; George L Drusano; David P Nicolau
Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem.
Clinical therapeutics 2004;26(8):1187-98.
2004: George L Drusano; Sandra L Preston; Cynthia Fowler; Michael Corrado; Barbara Weisinger; James Kahn
Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia.
The Journal of infectious diseases 2004;189(9):1590-7.
2004: George L Drusano
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.
Nature reviews. Microbiology 2004;2(4):289-300.
2004: George L Drusano; Sandra L Preston
A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus.
The Journal of infectious diseases 2004;189(6):964-70.
2004: James J McSharry; Ann C McDonough; Betty A Olson; George L Drusano
Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.
Clinical and diagnostic laboratory immunology 2004;11(1):21-8.
2003: Vincent H Tam; Sandra L Preston; George L Drusano
Comparative pharmacokinetic analysis by standard two-stage method versus nonparametric population modeling.
Pharmacotherapy 2003;23(12):1545-9.
2003: R Masterton; George L Drusano; David L Paterson; G Park
Appropriate antimicrobial treatment in nosocomial infections-the clinical challenges.
The Journal of hospital infection 2003;55 Suppl 1():1-12.
2003: John S Bradley; Michael N Dudley; George L Drusano
Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation.
The Pediatric infectious disease journal 2003;22(11):982-92; quiz 993-5.
2003: Sandra L Preston; Peter J Piliero; John Bilello; Daniel S Stein; William T Symonds; George L Drusano
In vitro-in vivo model for evaluating the antiviral activity of amprenavir in combination with ritonavir administered at 600 and 100 milligrams, respectively, every 12 hours.
Antimicrobial agents and chemotherapy 2003;47(11):3393-9.
2003: Sandra L Preston; Peter J Piliero; George L Drusano
Pharmacodynamics and clinical use of anti-HIV drugs.
Infectious disease clinics of North America 2003;17(3):651-74.
2003: Vincent H Tam; Sandra L Preston; George L Drusano
Optimal sampling schedule design for populations of patients.
Antimicrobial agents and chemotherapy 2003;47(9):2888-91.
2003: Nelson L Jumbe; Arnold Louie; Robert Leary; Weiguo Liu; Mark R Deziel; Vincent H Tam; Reetu Bachhawat; Christopher Freeman; James B Kahn; Karen Bush; Michael N Dudley; Michael H Miller; George L Drusano
Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.
The Journal of clinical investigation 2003;112(2):275-85.
2003: Vincent H Tam; Peggy S McKinnon; Ronda L Akins; George L Drusano; Michael J Rybak
Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function.
Antimicrobial agents and chemotherapy 2003;47(6):1853-61.
2003: Peter J Piliero; Douglas G Fish; Sandra Preston; Donna Cunningham; Tosca Kinchelow; Miklos Salgo; Jiang Qian; George L Drusano
Guillain-Barré syndrome associated with immune reconstitution.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;36(9):e111-4.
2003: Myong-Jin Kim; Anne N Nafziger; Clayton D Harro; Harry L Keyserling; Keith M Ramsey; George L Drusano; Joseph S Bertino
Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response.
Vaccine 2003;21(11-12):1174-9.
2003: Vincent H Tam; Arnold Louie; Ben M Lomaestro; George L Drusano
Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa.
Pharmacotherapy 2003;23(3):291-5.
2003: George L Drusano
Prevention of resistance: a goal for dose selection for antimicrobial agents.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;36(Suppl 1):S42-50.
2002: Vincent H Tam; Peggy S McKinnon; Ronda L Akins; Michael J Rybak; George L Drusano
Pharmacodynamics of cefepime in patients with Gram-negative infections.
The Journal of antimicrobial chemotherapy 2002;50(3):425-8.
2002: Mohammed M Hossain; Jason J Coull; George L Drusano; David M Margolis
Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir.
Antiviral research 2002;55(1):41-52.
2002: Johan W Mouton; Michael N Dudley; Otto Cars; Hartmut Derendorf; George L Drusano
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs.
International journal of antimicrobial agents 2002;19(4):355-8.
2002: George L Drusano; Katy H P Moore; JP Kleim; William T Prince; A Bye
Rational dose selection for a nonnucleoside reverse transcriptase inhibitor through use of population pharmacokinetic modeling and Monte Carlo simulation.
Antimicrobial agents and chemotherapy 2002;46(3):913-6.
2002: George L Drusano; Sandra L Preston; Mark H Gotfried; Larry H Danziger; Keith A Rodvold
Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and monte carlo simulation.
Antimicrobial agents and chemotherapy 2002;46(2):586-9.
2002: George L Drusano; P A Bilello; William T Symonds; Daniel S Stein; J McDowell; A Bye; John Bilello
Pharmacodynamics of abacavir in an in vitro hollow-fiber model system.
Antimicrobial agents and chemotherapy 2002;46(2):464-70.
2001: George L Drusano; S L Preston; Robert C Owens; Paul G Ambrose
Fluoroquinolone pharmacodynamics.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;33(12):2091-6.
2001: James J McSharry; Ann C McDonough; Betty Olson; Sabine Hallenberger; J Reefschlaeger; Wolfgang Bender; George L Drusano
Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir.
Antimicrobial agents and chemotherapy 2001;45(10):2925-7.
2001: George L Drusano; Sandra L Preston; D Smee; K Bush; K Bailey; R W Sidwell
Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing.
Antimicrobial agents and chemotherapy 2001;45(7):2115-8.
2001: Richard Hafner; J Bethel; HC Standiford; S Follansbee; David L Cohn; R E Polk; L Mole; Ralph H Raasch; P Kumar; D Mushatt; George L Drusano
Tolerance and pharmacokinetic interactions of rifabutin and azithromycin.
Antimicrobial agents and chemotherapy 2001;45(5):1572-7.
2001: George L Drusano; John Bilello; Sandra L Preston; E O'Mara; S Kaul; S Schnittman; R Echols
Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable.
The Journal of infectious diseases 2001;183(7):1126-9.
2001: Arnold Louie; P Kaw; Weiguo Liu; Nelson L Jumbe; Michael H Miller; George L Drusano
Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.
Antimicrobial agents and chemotherapy 2001;45(3):845-51.
2001: George L Drusano
Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2001;7 Suppl 3():24-9.
2001: George L Drusano; S L Preston; Catherine J Hardalo; R Hare; C Banfield; David Andes; Omar Vesga; William A Craig
Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint.
Antimicrobial agents and chemotherapy 2001;45(1):13-22.
2000: George L Drusano
Fluoroquinolone pharmacodynamics: prospective determination of relationships between exposure and outcome.
Journal of chemotherapy (Florence, Italy) 2000;12 Suppl 4():21-6.
2000: George L Drusano; Sandra L Preston; M Van Guilder; D North; M Gombert; M Oefelein; L Boccumini; B Weisinger; Michael Corrado; J Kahn
A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin.
Antimicrobial agents and chemotherapy 2000;44(8):2046-51.
2000: George L Drusano; DZ D'Argenio; Sandra L Preston; C Barone; William T Symonds; Steve Lafon; M Rogers; William T Prince; A Bye; John Bilello
Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir.
Antimicrobial agents and chemotherapy 2000;44(6):1655-9.
2000: George L Drusano; Hartmut Lode; J R Edwards
Meropenem: clinical response in relation to in vitro susceptibility.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2000;6(4):185-94.
2000: Stuart Snyder; DZ D'Argenio; O Weislow; John Bilello; George L Drusano
The triple combination indinavir-zidovudine-lamivudine is highly synergistic.
Antimicrobial agents and chemotherapy 2000;44(4):1051-8.
2000: E M Hanley; A Veeder; T Smith; George L Drusano; E Currie; Richard A Venezia
Evaluation of an antiseptic triple-lumen catheter in an intensive care unit.
Critical care medicine 2000;28(2):366-70.
1999: Arnold Louie; P Banerjee; George L Drusano; M Shayegani; Michael H Miller
Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans.
Antimicrobial agents and chemotherapy 1999;43(12):2841-7.
1999: Arnold Louie; Weiguo Liu; D A Miller; A C Sucke; QF Liu; George L Drusano; Martin Mayers; Michael H Miller
Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans.
Antimicrobial agents and chemotherapy 1999;43(12):2831-40.
1999: Sandra L Preston; George L Drusano; P Glue; J Nash; S K Gupta; P McNamara
Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology.
Antimicrobial agents and chemotherapy 1999;43(10):2451-6.
1999: Gail Skowron; Daniel S Stein; George L Drusano; K Melbourne; John Bilello; D Mikolich; K Rana; JM Agosti; A Mongillo; JB Whitmore; Mark J Gilbert
The safety and efficacy of granulocyte-macrophage colony-stimulating factor (Sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: a randomized double-blind, placebo-controlled trial.
The Journal of infectious diseases 1999;180(4):1064-71.
1999: David Margolis; Alonso Heredia; Jariyanart Gaywee; David W Oldach; George L Drusano; Robert R Redfield
Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity.
Journal of acquired immune deficiency syndromes (1999) 1999;21(5):362-70.
1999: FP Tally; M Zeckel; M M Wasilewski; C Carini; CL Berman; George L Drusano; FB Oleson
Daptomycin: a novel agent for Gram-positive infections.
Expert opinion on investigational drugs 1999;8(8):1223-38.
1999: Richard Hafner; Clark B Inderlied; Dolores M Peterson; D J Wright; HC Standiford; George L Drusano; K Muth
Correlation of quantitative bone marrow and blood cultures in AIDS patients with disseminated Mycobacterium avium complex infection.
The Journal of infectious diseases 1999;180(2):438-47.
1999: Michael J Rybak; B J Abate; S L Kang; M J Ruffing; Stephen A Lerner; George L Drusano
Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity.
Antimicrobial agents and chemotherapy 1999;43(7):1549-55.
1999: Angela D M Kashuba; Anne N Nafziger; George L Drusano; Joseph S Bertino
Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria.
Antimicrobial agents and chemotherapy 1999;43(3):623-9.
1998: James J McSharry; Nell S Lurain; George L Drusano; A L Landay; M Notka; Maurice O'Gorman; A Weinberg; HM Shapiro; Patricia Reichelderfer; Clyde S Crumpacker
Rapid ganciclovir susceptibility assay using flow cytometry for human cytomegalovirus clinical isolates.
Antimicrobial agents and chemotherapy 1998;42(9):2326-31.
1998: George L Drusano; DZ D'Argenio; William T Symonds; P A Bilello; J McDowell; B Sadler; A Bye; John Bilello
Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro.
Antimicrobial agents and chemotherapy 1998;42(9):2153-9.
1998: George L Drusano
Infection in the intensive care unit: beta-lactamase-mediated resistance among Enterobacteriaceae and optimal antimicrobial dosing.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998;27 Suppl 1():S111-6.
1998: George L Drusano; John Bilello; Daniel S Stein; M Nessly; Anne R Meibohm; Emilio A Emini; P Deutsch; Jon H Condra; Jeffrey A Chodakewitz; Daniel J Holder
Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables.
The Journal of infectious diseases 1998;178(2):360-7.
1998: Arnold Louie; QF Liu; George L Drusano; Weiguo Liu; Martin Mayers; E Anaissie; Michael H Miller
Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans.
Antimicrobial agents and chemotherapy 1998;42(6):1512-4.
1998: Weiguo Liu; QF Liu; R Perkins; George L Drusano; Arnold Louie; Assumpta Madu; Umar Mian; Martin Mayers; Michael H Miller
Pharmacokinetics of sparfloxacin in the serum and vitreous humor of rabbits: physicochemical properties that regulate penetration of quinolone antimicrobials.
Antimicrobial agents and chemotherapy 1998;42(6):1417-23.
1998: Arnold Louie; George L Drusano; P Banerjee; QF Liu; Weiguo Liu; P Kaw; M Shayegani; H Taber; Michael H Miller
Pharmacodynamics of fluconazole in a murine model of systemic candidiasis.
Antimicrobial agents and chemotherapy 1998;42(5):1105-9.
1998: Sandra L Preston; George L Drusano; A L Berman; Cynthia L Fowler; Andrew T Chow; B Dornseif; V Reichl; Jaya Natarajan; Frankie A Wong; Michael Corrado
Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.
Antimicrobial agents and chemotherapy 1998;42(5):1098-104.
1998: J M McSharry; Nell S Lurain; George L Drusano; A Landay; J Manischewitz; Mostafa Nokta; Maurice O'Gorman; HM Shapiro; A Weinberg; Patricia Reichelderfer; Clyde S Crumpacker
Flow cytometric determination of ganciclovir susceptibilities of human cytomegalovirus clinical isolates.
Journal of clinical microbiology 1998;36(4):958-64.
1998: Richard Hafner; J Bethel; M Power; Bernard S Landry; M Banach; L Mole; HC Standiford; S Follansbee; P Kumar; Ralph H Raasch; D Cohn; D Mushatt; George L Drusano
Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.
Antimicrobial agents and chemotherapy 1998;42(3):631-9.
1998: George L Drusano; Daniel S Stein
Mathematical modeling of the interrelationship of CD4 lymphocyte count and viral load changes induced by the protease inhibitor indinavir.
Antimicrobial agents and chemotherapy 1998;42(2):358-61.
1998: Sandra L Preston; George L Drusano; A L Berman; Cynthia L Fowler; Andrew T Chow; B Dornseif; V Reichl; Jaya Natarajan; Michael Corrado
Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials.
JAMA : the journal of the American Medical Association 1998;279(2):125-9.
1997: Scott A Gruber; Michael H Gallichio; Thomas G Rosano; S S Kaplan; S E Hughes; D L Urbauer; T Paul Singh; N Lempert; David J Conti; D S Stein; George L Drusano
Comparative pharmacokinetics and renal effects of cyclosporin A and cyclosporin G in renal allograft recipients.
Journal of clinical pharmacology 1997;37(7):575-86.
1997: George L Drusano; W A Craig
Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections.
Journal of chemotherapy (Florence, Italy) 1997;9 Suppl 3():38-44.
1997: Daniel S Stein; George L Drusano
Modeling of the change in CD4 lymphocyte counts in patients before and after administration of the human immunodeficiency virus protease inhibitor indinavir.
Antimicrobial agents and chemotherapy 1997;41(2):449-53.
1996: George L Drusano; Francesca T Aweeka; JG Gambertoglio; M Jacobson; M Polis; H Clifford Lane; C Eaton; S Martin-Munley
Relationship between foscarnet exposure, baseline cytomegalovirus (CMV) blood culture and the time to progression of CMV retinitis in HIV-positive patients.
AIDS (London, England) 1996;10(10):1113-9.
1996: Assumpta Madu; Martin Mayers; R Perkins; Weiguo Liu; George L Drusano; R Aswani; C N Madu; Michael H Miller
Aqueous and vitreous penetration of ciprofloxacin following different modes of systemic administration.
Experimental eye research 1996;63(2):129-36.
1996: George L Drusano; F W Goldstein
Relevance of the Alexander Project: pharmacodynamic considerations.
The Journal of antimicrobial chemotherapy 1996;38 Suppl A():141-54.
1996: D S Stein; H Dunn; George L Drusano
Acute thrombocytopenia secondary to the administration of the peptidomimetic HIV protease inhibitor MK-639(L735524)
AIDS (London, England) 1996;10(6):678-80.
1996: John Bilello; P A Bilello; K Stellrecht; J Leonard; Daniel W Norbeck; Dale J Kempf; T Robins; George L Drusano
Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease.
Antimicrobial agents and chemotherapy 1996;40(6):1491-7.
1996: John Bilello; George L Drusano
Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease.
The Journal of infectious diseases 1996;173(6):1524-6.
1996: D S Stein; D G Fish; John Bilello; Sandra L Preston; G L Martineau; George L Drusano
A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir).
AIDS (London, England) 1996;10(5):485-92.
1996: George L Drusano; Mark Prichard; P A Bilello; John Bilello
Modeling combinations of antiretroviral agents in vitro with integration of pharmacokinetics: guidance in regimen choice for clinical trial evaluation.
Antimicrobial agents and chemotherapy 1996;40(5):1143-7.
1996: S L Preston; George L Drusano
Nonparametric expectation maximization population modeling of ganciclovir.
Journal of clinical pharmacology 1996;36(4):301-10.
1996: Scott A Gruber; M Gallichio; Thomas G Rosano; S E Hughes; T Paul Singh; N Lempert; David J Conti; J Hasselbarth; Brian M Freed; D Stein; George L Drusano
Comparative pharmacokinetics of cyclosporine A and cyclosporine G in renal allograft recipients.
Transplantation proceedings 1996;28(2):892.
1996: John Bilello; K Stellrecht; George L Drusano; D S Stein
Soluble tumor necrosis factor-alpha receptor type II (sTNF alpha RII) correlates with human immunodeficiency virus (HIV) RNA copy number in HIV-infected patients.
The Journal of infectious diseases 1996;173(2):464-7.
1996: M S Simberkoff; P M Hartigan; J D Hamilton; P L Day; G R Diamond; Gordon M Dickinson; George L Drusano; Merrill J Egorin; W L George; F M Gordin; C A Hawkes; P C Jensen; N G Kilmas; A M Labriola; William A O'Brien; C N Oster; K J Weinhold; Nelda P Wray; S B Pazner
Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Group on AIDS Treatment.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996;11(2):142-50.
1995: S L Preston; Laurie L Briceland; B M Lomaestro; T S Lesar; George R Bailie; George L Drusano
Dosing adjustment of 10 antimicrobials for patients with renal impairment.
The Annals of pharmacotherapy 1995;29(12):1202-7.
1995: John Bilello; P A Bilello; J J Kort; M N Dudley; J Leonard; George L Drusano
Efficacy of constant infusion of A-77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, in limiting acute HIV-1 infection in vitro.
Antimicrobial agents and chemotherapy 1995;39(11):2523-7.
1995: G J Yuen; George L Drusano; C Fletcher; E Capparelli; James D Connor; Jacob P Lalezari; L Drew; S Follansbee; D Busch; M Jacobson
Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling.
Antimicrobial agents and chemotherapy 1995;39(10):2350-2.
1995: George L Drusano; Weiguo Liu; R Perkins; Assumpta Madu; C Madu; Martin Mayers; Michael H Miller
Determination of robust ocular pharmacokinetic parameters in serum and vitreous humor of albino rabbits following systemic administration of ciprofloxacin from sparse data sets by using IT2S, a population pharmacokinetic modeling program.
Antimicrobial agents and chemotherapy 1995;39(8):1683-7.
1995: R J Perkins; Weiguo Liu; George L Drusano; Assumpta Madu; Martin Mayers; C Madu; Michael H Miller
Pharmacokinetics of ofloxacin in serum and vitreous humor of albino and pigmented rabbits.
Antimicrobial agents and chemotherapy 1995;39(7):1493-8.
1995: John Bilello; P A Bilello; Mark Prichard; T Robins; George L Drusano
Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoprotein.
The Journal of infectious diseases 1995;171(3):546-51.
1995: George L Drusano; M Hutchison
The pharmacokinetics of meropenem.
Scandinavian journal of infectious diseases. Supplementum 1995;96():11-6.
1994: George L Drusano; A Forrest; G Yuen; K Plaisance; J Leslie
Optimal sampling theory: effect of error in a nominal parameter value on bias and precision of parameter estimation.
Journal of clinical pharmacology 1994;34(10):967-74.
1994: George L Drusano; FRANK BALIS; S R Gitterman; P A Pizzo
Quantitative relationships between zidovudine exposure and efficacy and toxicity.
Antimicrobial agents and chemotherapy 1994;38(8):1726-31.
1994: John Bilello; Gerhard Bauer; M N Dudley; G A Cole; George L Drusano
Effect of 2',3'-didehydro-3'-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies.
Antimicrobial agents and chemotherapy 1994;38(6):1386-91.
1994: John Bilello; Julie L Eiseman; HC Standiford; George L Drusano
Impact of dosing schedule upon suppression of a retrovirus in a murine model of AIDS encephalopathy.
Antimicrobial agents and chemotherapy 1994;38(3):628-31.
1993: Anna Trifillis; X Cui; George L Drusano
Use of human renal proximal tubule cell cultures for studying foscarnet-induced nephrotoxicity in vitro.
Antimicrobial agents and chemotherapy 1993;37(11):2496-9.
1993: George L Drusano
Pharmacodynamics of antiretroviral chemotherapy.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 1993;14(9):530-6.
1993: HC Standiford; THOMAS WALSH; George L Drusano; B A Tatem; R J Townsend
Serum inhibitory and bactericidal activity against methicillin-resistant Staphylococcus aureus in volunteers receiving novobiocin and rifampin alone and in combination.
Diagnostic microbiology and infectious disease 1993;17(2):135-42.
1993: George L Drusano; David E Johnson; M Rosen; HC Standiford
Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis.
Antimicrobial agents and chemotherapy 1993;37(3):483-90.
1993: J J Kort; John Bilello; Gerhard Bauer; George L Drusano
Preclinical evaluation of antiviral activity and toxicity of Abbott A77003, an inhibitor of the human immunodeficiency virus type 1 protease.
Antimicrobial agents and chemotherapy 1993;37(1):115-9.
1992: Walter R Wilson; D N Gilbert; Alan L Bisno; L R Freedman; C Smith; George L Drusano; D Kaye
Evaluation of new anti-infective drugs for the treatment of infective endocarditis. Infectious Diseases Society of America and the Food and Drug Administration.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1992;15 Suppl 1():S89-95.
1992: George L Drusano; G J Yuen; Gene D Morse; T P Cooley; M Seidlin; John S Lambert; Howard A Liebman; Fred Valentine; Raphael Dolin
Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials.
Antimicrobial agents and chemotherapy 1992;36(6):1280-3.
1992: George L Drusano; G J Yuen; John S Lambert; M Seidlin; Raphael Dolin; Fred Valentine
Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. A phase I trial.
Annals of internal medicine 1992;116(7):562-6.
1992: J D Hamilton; P M Hartigan; M S Simberkoff; P L Day; G R Diamond; Gordon M Dickinson; George L Drusano; Merrill J Egorin; W L George; F M Gordin
A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study.
The New England journal of medicine 1992;326(7):437-43.
1992: G J Yuen; George L Drusano; J Brooks; S Flor
Use of nonlinear, mixed-effects modeling for population analysis of ofloxacin: effects of age on oral drug pharmacokinetics.
Pharmacotherapy 1992;12(2):88-92.
1991: George L Drusano
Optimal sampling theory and population modelling: application to determination of the influence of the microgravity environment on drug distribution and elimination.
Journal of clinical pharmacology 1991;31(10):962-7.
1990: S R Gitterman; George L Drusano; Merrill J Egorin; HC Standiford
Population pharmacokinetics of zidovudine. The Veterans Administration Cooperative Studies Group.
Clinical pharmacology and therapeutics 1990;48(2):161-7.
1990: K I Plaisance; George L Drusano; A Forrest; Matthew R Weir; HC Standiford
Effect of renal function on the bioavailability of ciprofloxacin.
Antimicrobial agents and chemotherapy 1990;34(6):1031-4.
1990: George L Drusano
Human pharmacodynamics of beta-lactams, aminoglycosides and their combination.
Scandinavian journal of infectious diseases. Supplementum 1990;74():235-48.
1989: G J Yuen; George L Drusano; K Plaisance; A Forrest; Ellis Caplan
Ciprofloxacin pharmacokinetics in critically ill trauma patients.
The American journal of medicine 1989;87(5A):70S-75S.
1989: G J Yuen; George L Drusano; A Forrest; K Plaisance; Ellis Caplan
Prospective use of optimal sampling theory: steady-state ciprofloxacin pharmacokinetics in critically ill trauma patients.
Clinical pharmacology and therapeutics 1989;46(4):451-7.
1989: B S Margaret; George L Drusano; HC Standiford
Emergence of resistance to carbapenem antibiotics in Pseudomonas aeruginosa.
The Journal of antimicrobial chemotherapy 1989;24 Suppl A():161-7.
1989: George L Drusano; A Forrest; K I Plaisance; J C Wade
A prospective evaluation of optimal sampling theory in the determination of the steady-state pharmacokinetics of piperacillin in febrile neutropenic cancer patients.
Clinical pharmacology and therapeutics 1989;45(6):635-41.
1989: K I Plaisance; George L Drusano; A Forrest; R J Townsend; HC Standiford
Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate.
Antimicrobial agents and chemotherapy 1989;33(5):618-20.
1989: S J Savarino; Margaret B Rennels; George L Drusano
Pseudomonas meningitis therapy recommendation questioned.
Pediatrics 1989;83(4 Pt 2):632-3.
1988: A Forrest; Matthew R Weir; K I Plaisance; George L Drusano; James L Leslie; HC Standiford
Relationships between renal function and disposition of oral ciprofloxacin.
Antimicrobial agents and chemotherapy 1988;32(10):1537-40.
1988: George L Drusano; A Forrest; M J Snyder; M D Reed; J L Blumer
An evaluation of optimal sampling strategy and adaptive study design.
Clinical pharmacology and therapeutics 1988;44(2):232-8.
1988: C Ferreccio; J Glenn Morris; C Valdivieso; I Prenzel; V Sotomayor; George L Drusano; Myron M Levine
Efficacy of ciprofloxacin in the treatment of chronic typhoid carriers.
The Journal of infectious diseases 1988;157(6):1235-9.
1988: George L Drusano; H L Munice; J M Hoopes; D Damron; John W Warren
Commonly used methods of estimating creatinine clearance are inadequate for elderly debilitated nursing home patients.
Journal of the American Geriatrics Society 1988;36(5):437-41.
1988: George L Drusano
Role of pharmacokinetics in the outcome of infections.
Antimicrobial agents and chemotherapy 1988;32(3):289-97.
1987: M J Lynch; George L Drusano; harry mobley
Emergence of resistance to imipenem in Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy 1987;31(12):1892-6.
1987: George L Drusano; K I Plaisance; A Forrest; C Bustamante; A Devlin; HC Standiford; J C Wade
Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients.
Antimicrobial agents and chemotherapy 1987;31(9):1420-2.
1987: HC Standiford; George L Drusano; A Forrest; B Tatem; K Plaisance
Bactericidal activity of ciprofloxacin compared with that of cefotaxime in normal volunteers.
Antimicrobial agents and chemotherapy 1987;31(8):1177-82.
1987: K I Plaisance; George L Drusano; A Forrest; C I Bustamante; HC Standiford
Effect of dose size on bioavailability of ciprofloxacin.
Antimicrobial agents and chemotherapy 1987;31(6):956-8.
1987: George L Drusano; Matthew R Weir; A Forrest; K Plaisance; T Emm; HC Standiford
Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function.
Antimicrobial agents and chemotherapy 1987;31(6):860-4.
1987: George L Drusano
An overview of the pharmacology of intravenously administered ciprofloxacin.
The American journal of medicine 1987;82(4A):339-45.
1987: C I Bustamante; George L Drusano; R C Wharton; J C Wade
Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomonas aeruginosa and other bacterial pathogens.
Antimicrobial agents and chemotherapy 1987;31(4):632-4.
1986: George L Drusano
An overview of the pharmacology of imipenem/cilastatin.
The Journal of antimicrobial chemotherapy 1986;18 Suppl E():79-92.
1986: George L Drusano; HC Standiford; K Plaisance; A Forrest; J Leslie; J Caldwell
Absolute oral bioavailability of ciprofloxacin.
Antimicrobial agents and chemotherapy 1986;30(3):444-6.
1986: George L Drusano; K I Plaisance; A Forrest; HC Standiford
Dose ranging study and constant infusion evaluation of ciprofloxacin.
Antimicrobial agents and chemotherapy 1986;30(3):440-3.
1986: George L Drusano; R J Townsend; THOMAS WALSH; A Forrest; E J Antal; HC Standiford
Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination.
Antimicrobial agents and chemotherapy 1986;30(1):42-5.
1986: Manjari Joshi; WILLIAM ANTHONY; J H Tenney; George L Drusano; Ellis Caplan; HC Standiford; A Henson; John W Warren
Double-blind, prospective, multicenter trial comparing ceftazidime with moxalactam in the treatment of serious gram-negative infections.
Antimicrobial agents and chemotherapy 1986;30(1):90-5.
1986: C A De Jongh; J H Joshi; B W Thompson; K A Newman; R S Finley; M R Moody; P C Salvatore; J H Tenney; George L Drusano; Stephen C Schimpff
A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients.
The American journal of medicine 1986;80(5C):101-11.
1986: HC Standiford; George L Drusano; C I Bustamante; G Rivera; A Forrest; B Tatem; J Leslie; M Moody
Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers.
Antimicrobial agents and chemotherapy 1986;29(3):412-7.
1986: George L Drusano; HC Standiford; P Ryan; W McNamee; B Tatem; Stephen C Schimpff
Correlation of predicted serum bactericidal activities and values measured in volunteers.
European journal of clinical microbiology 1986;5(1):88-92.
1986: Stephen C Schimpff; George L Drusano; HC Standiford
Serum bactericidal test in volunteers--a review.
European journal of clinical microbiology 1986;5(1):71-8.
1985: R F Khabbaz; HC Standiford; D Bernstein; H C Nipper; B A Tatem; U Smalls; George L Drusano; Ellis Caplan
Measurement of amikacin in serum by a latex agglutination inhibition test.
Journal of clinical microbiology 1985;22(5):699-701.
1985: J Glenn Morris; J H Tenney; George L Drusano
In vitro susceptibility of pathogenic Vibrio species to norfloxacin and six other antimicrobial agents.
Antimicrobial agents and chemotherapy 1985;28(3):442-5.
1985: M A Gonzalez; A H Moranchel; S Duran; A Pichardo; J L Magana; B Painter; A Forrest; George L Drusano
Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers.
Antimicrobial agents and chemotherapy 1985;28(2):235-9.
1985: J C Wade; HC Standiford; George L Drusano; David E Johnson; M R Moody; C I Bustamante; J H Joshi; C deJongh; Stephen C Schimpff
Potential of imipenem as single-agent empiric antibiotic therapy of febrile neutropenic patients with cancer.
The American journal of medicine 1985;78(6A):62-72.
1985: George L Drusano; HC Standiford
Pharmacokinetic profile of imipenem/cilastatin in normal volunteers.
The American journal of medicine 1985;78(6A):47-53.
1985: M A Gonzalez; A H Moranchel; S Duran; A Pichardo; J L Magana; B Painter; George L Drusano
Multiple-dose ciprofloxacin dose ranging and kinetics.
Clinical pharmacology and therapeutics 1985;37(6):633-7.
1985: A F Viollier; HC Standiford; George L Drusano; B A Tatem; M R Moody; Stephen C Schimpff
Comparative pharmacokinetics and serum bactericidal activity of mezlocillin, ticarcillin and piperacillin, with and without gentamicin.
The Journal of antimicrobial chemotherapy 1985;15(5):597-606.
1985: George L Drusano; HC Standiford; C I Bustamante; G Rivera; A Forrest; J Leslie; B Tatem; D Delaportas; Stephen C Schimpff
Safety and tolerability of multiple doses of imipenem/cilastatin.
Clinical pharmacology and therapeutics 1985;37(5):539-43.
1985: George L Drusano; J Joshi; A Forrest; R Ruxer; HC Standiford; J Leslie; J Wade; Stephen C Schimpff
Pharmacokinetics of ceftazidime, alone or in combination with piperacillin or tobramycin, in the sera of cancer patients.
Antimicrobial agents and chemotherapy 1985;27(4):605-7.
1985: George L Drusano; C de Jongh; K Newman; J Joshi; R Wharton; M R Moody; Stephen C Schimpff
Moxalactam and piperacillin: a study of in vitro characteristics and pharmacokinetics in cancer patients.
Infection 1985;13(1):20-6.
1984: D Herrington; George L Drusano; U Smalls; HC Standiford
False elevation in serum creatinine levels.
JAMA : the journal of the American Medical Association 1984;252(21):2962.
1984: George L Drusano; HC Standiford; C Bustamante; A Forrest; G Rivera; J Leslie; B Tatem; D Delaportas; R R MacGregor; Stephen C Schimpff
Multiple-dose pharmacokinetics of imipenem-cilastatin.
Antimicrobial agents and chemotherapy 1984;26(5):715-21.
1984: D Fiore; francois auger; George L Drusano; V R Dandu; L J Lesko
Improved micromethod for mezlocillin quantitation in serum and urine by high-pressure liquid chromatography.
Antimicrobial agents and chemotherapy 1984;26(5):775-7.
1984: George L Drusano; A Forrest; D Fiore; F Auger; Ellis Caplan
Effect of saturable clearance during high-dose mezlocillin therapy.
Antimicrobial agents and chemotherapy 1984;26(5):686-8.
1984: C I Bustamante; George L Drusano; B A Tatem; HC Standiford
Postantibiotic effect of imipenem on Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy 1984;26(5):678-82.
1984: W McNamee; George L Drusano; B A Tatem; HC Standiford
The serum bactericidal activity of latamoxef (moxalactam), cefoperazone and cefotaxime.
The Journal of antimicrobial chemotherapy 1984;14(5):491-7.
1984: George L Drusano; HC Standiford; C I Bustamante; A Forrest; G Rivera; B Tatem; Stephen C Schimpff
The plasma pharmacokinetics of high dose (1 g) imipenem coadministered with 1 g cilastatin in six normal volunteers.
European journal of clinical microbiology 1984;3(5):468-70.
1984: HC Standiford; George L Drusano; B Fitzpatrick; B Tatem; Stephen C Schimpff
Bactericidal activity of ceftazidime in serum compared with that of ticarcillin combined with amikacin.
Antimicrobial agents and chemotherapy 1984;26(3):339-42.
1984: George L Drusano; HC Standiford; B Fitzpatrick; J Leslie; P Tangtatsawasdi; P Ryan; B Tatem; M R Moody; Stephen C Schimpff
Comparison of the pharmacokinetics of ceftazidime and moxalactam and their microbiological correlates in volunteers.
Antimicrobial agents and chemotherapy 1984;26(3):388-93.
1984: M H Kroll; T R Koch; George L Drusano; John W Warren
Lack of interference with creatinine assays by four cephalosporin-like antibiotics.
American journal of clinical pathology 1984;82(2):214-6.
1984: George L Drusano; P A Ryan; HC Standiford; M R Moody; Stephen C Schimpff
Integration of selected pharmacologic and microbiologic properties of three new beta-lactam antibiotics: a hypothesis for rational comparison.
Reviews of infectious diseases 1984;6(3):357-63.
1984: George L Drusano; Stephen C Schimpff; W L Hewitt
The acylampicillins: mezlocillin, piperacillin, and azlocillin.
Reviews of infectious diseases 1984;6(1):13-32.
1982: HC Standiford; George L Drusano; W B McNamee; B Tatem; P A Ryan; Stephen C Schimpff
Comparative pharmacokinetics of moxalactam, cefoperazone, and cefotaxime in normal volunteers.
Reviews of infectious diseases 1982;4 Suppl():S585-94.
1982: George L Drusano; John W Warren; A J Saah; Ellis Caplan; J H Tenney; S Hansen; J Granados; HC Standiford; E H Miller
A prospective randomized controlled trial of cefoxitin versus clindamycin-aminoglycoside in mixed anaerobic-aerobic infections.
Surgery, gynecology & obstetrics 1982;154(5):715-20.
1982: A J Saah; T R Koch; George L Drusano
Cefoxitin falsely elevates creatinine levels.
JAMA : the journal of the American Medical Association 1982;247(2):205-6.
1981: M L Clements; Myron M Levine; Robert E Black; R M Robins-Browne; L A Cisneros; George L Drusano; Claudio F Lanata; A J Saah
Lactobacillus prophylaxis for diarrhea due to enterotoxigenic Escherichia coli.
Antimicrobial agents and chemotherapy 1981;20(1):104-8.
1981: A J Saah; George L Drusano; John W Warren; J H Tenney; Ellis Caplan
Cefoxitin-resistant facultative or aerobic gram-negative bacilli in infections associated with the gastrointestinal tract.
Annals of internal medicine 1981;94(4 pt 1):487-8.
1981: S L Hansen; P Swomley; George L Drusano
Effect of carbon dioxide and pH on susceptibility of Bacteroides fragilis group to erythromycin.
Antimicrobial agents and chemotherapy 1981;19(2):335-6.